Kathryn M. Cappell

Oncology · 2023

A researcher in the Science corpus: 1 paper; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Kathryn M. Cappell trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. J. Kochenderfer
  2. D. Porter
  3. Jennifer N. Brudno

Papers from Kathryn M. Cappell's perspective

Ordered by how strongly the researchers Kathryn M. Cappell trusts endorse each paper. Same corpus, a different order for every researcher.

  1. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia (Science Translational Medicine)
  2. Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia (New England Journal of Medicine)
  3. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. (Journal of Clinical Investigation)
  4. KTE-X19 for relapsed/refractory adult B-cell acute lymphoblastic leukemia: phase 2 results from the single-arm, multicenter ZUMA-3 study (The Lancet)
  5. Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma (New England Journal of Medicine)
  6. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. (New England Journal of Medicine)
  7. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells (Nature)
  8. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. (Blood)
  9. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells (Cancer Discovery)
  10. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia (Science Translational Medicine)

Their papers